These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23730884)

  • 1. The road to remyelination in demyelinating diseases: current status and prospects for clinical treatment.
    Wootla B; Watzlawik JO; Denic A; Rodriguez M
    Expert Rev Clin Immunol; 2013 Jun; 9(6):535-49. PubMed ID: 23730884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-mediated CNS demyelination II. Focal spinal cord lesions induced by implantation of an IgM antisulfatide-secreting hybridoma.
    Rosenbluth J; Schiff R; Liang WL; Dou W
    J Neurocytol; 2003 Mar; 32(3):265-76. PubMed ID: 14724389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Molecular Basis for Remyelination Failure in Multiple Sclerosis.
    Gruchot J; Weyers V; Göttle P; Förster M; Hartung HP; Küry P; Kremer D
    Cells; 2019 Aug; 8(8):. PubMed ID: 31382620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive human immunity drives remyelination in a mouse model of demyelination.
    El Behi M; Sanson C; Bachelin C; Guillot-Noël L; Fransson J; Stankoff B; Maillart E; Sarrazin N; Guillemot V; Abdi H; Cournu-Rebeix I; Fontaine B; Zujovic V
    Brain; 2017 Apr; 140(4):967-980. PubMed ID: 28334918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Method of identifying natural antibodies for remyelination.
    Warrington AE; Rodriguez M
    J Clin Immunol; 2010 May; 30 Suppl 1(0 1):S50-5. PubMed ID: 20387101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-mediated remyelination: relevance to multiple sclerosis.
    Bieber A; Asakura K; Warrington A; Kaveri SV; Rodriguez M
    Mult Scler; 2000 Oct; 6 Suppl 2():S1-5; discussion S33. PubMed ID: 11188771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cells of the oligodendroglial lineage, myelination, and remyelination.
    Miron VE; Kuhlmann T; Antel JP
    Biochim Biophys Acta; 2011 Feb; 1812(2):184-93. PubMed ID: 20887785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis.
    Wolswijk G
    Brain; 2000 Jan; 123 ( Pt 1)():105-15. PubMed ID: 10611125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogeneous remyelination: findings in human studies.
    Kipp M; Victor M; Martino G; Franklin RJ
    CNS Neurol Disord Drug Targets; 2012 Aug; 11(5):598-609. PubMed ID: 22583436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remyelinating strategies in multiple sclerosis.
    Luessi F; Kuhlmann T; Zipp F
    Expert Rev Neurother; 2014 Nov; 14(11):1315-34. PubMed ID: 25331418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The complex world of oligodendroglial differentiation inhibitors.
    Kremer D; Aktas O; Hartung HP; Küry P
    Ann Neurol; 2011 Apr; 69(4):602-18. PubMed ID: 21520230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remyelination in multiple sclerosis.
    Chari DM
    Int Rev Neurobiol; 2007; 79():589-620. PubMed ID: 17531860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of interferon-beta leads to accelerated remyelination in a toxic model of central nervous system demyelination.
    Trebst C; Heine S; Lienenklaus S; Lindner M; Baumgärtner W; Weiss S; Stangel M
    Acta Neuropathol; 2007 Dec; 114(6):587-96. PubMed ID: 17940777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cellular and molecular events of central nervous system remyelination.
    Dubois-Dalcq M; Armstrong R
    Bioessays; 1990 Dec; 12(12):569-76. PubMed ID: 2080911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remyelination-promoting human IgMs: developing a therapeutic reagent for demyelinating disease.
    Warrington AE; Rodriguez M
    Curr Top Microbiol Immunol; 2008; 318():213-39. PubMed ID: 18219820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease.
    Mitsunaga Y; Ciric B; Van Keulen V; Warrington AE; Paz Soldan M; Bieber AJ; Rodriguez M; Pease LR
    FASEB J; 2002 Aug; 16(10):1325-7. PubMed ID: 12154009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The adult oligodendrocyte can participate in remyelination.
    Duncan ID; Radcliff AB; Heidari M; Kidd G; August BK; Wierenga LA
    Proc Natl Acad Sci U S A; 2018 Dec; 115(50):E11807-E11816. PubMed ID: 30487224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal remyelination-promoting natural autoantibody SCH 94.03: pharmacokinetics and in vivo targets within demyelinated spinal cord in a mouse model of multiple sclerosis.
    Hunter SF; Miller DJ; Rodriguez M
    J Neurol Sci; 1997 Sep; 150(2):103-13. PubMed ID: 9268236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A recombinant human IgM promotes myelin repair after a single, very low dose.
    Warrington AE; Bieber AJ; Ciric B; Pease LR; Van Keulen V; Rodriguez M
    J Neurosci Res; 2007 Apr; 85(5):967-76. PubMed ID: 17304578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of CXCR2 signaling promotes recovery in models of multiple sclerosis.
    Kerstetter AE; Padovani-Claudio DA; Bai L; Miller RH
    Exp Neurol; 2009 Nov; 220(1):44-56. PubMed ID: 19616545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.